

# Overview of R&D Activities

CHUGAI PHARMACEUTICAL CO., LTD.  
Senior Vice President  
Head of Lifecycle Management Marketing Unit  
Tatsuro Kosaka

July 31/August 1, 2008

# Forward Looking Statements

---

This presentation may include forward looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

# Projects under Development (as of July 2008)

	Phase I	Phase II	Phase III	Filed
Oncology	<i>R1273 (BC)</i> <i>TP300 (CRC)</i> <i>CIF (solid tumor)</i>	<i>Actemra (multiple myeloma)</i> <i>Avastin (NSCLC)</i> <i>Avastin (BC)</i> <i>Tarceva (PC)</i> <i>R744 (Mircera CIA)</i>	<i>Epogin (CIA)</i> <i>Avastin (Adj. CC)#</i> <i>Avastin (GC)#</i> <i>Avastin (Adj. BC)#</i> <i>Herceptin (GC)#</i> <i>Xeloda (GC)</i>	<i>Xeloda (CRC/ combo)</i>
Bone & Joint		<i>R484 (Bonviva oral osteoporosis)</i>	<i>R484 (Bonviva iv osteoporosis)</i> <i>ED-71 (osteoporosis)</i> <i>Actemra (sJIA)</i> <i>R1594 (RA) #</i>	<i>Actemra (RA)</i>
Renal			<i>R744 (Mircera renal anemia)</i>	
Transplant, Immunology Infection	<i>Actemra (SLE)</i> <i>Actemra (castleman's disease)</i> <i>NA808 (chronic hepatitis C)</i>	<i>Actemra (crohn's disease)</i>	<i>Pegasys / Copegus (liver cirrhosis)</i> <i>Pegasys (chronic hepatitis B)</i>	
Others	<i>*GM-611 (diabetic gastroparesis)</i> <i>R1583 (type II diabetes)</i> <i>CSG452 (type II diabetes)</i> <i>R1579 (type II diabetes)</i>	<i>*GM-611 (IBS)</i> <i>*GM-611 (diabetic gastroparesis)</i> <i>R1678 (schizophrenia) #</i>		<i>Epogin (autologous transfusion)</i>

\*GM-611 is being considered for out-licensing

(Italics: Roche projects, Underlined: overseas' clinical development, #: participation in multi-national studies)


## R&D Topics (April ~ July 2008)

---

- May R435 (Avastin) :Joined multinational phase III study conducted by Roche for adjuvant breast cancer
- May ED-71 :Entered into an agreement with Taisho Pharmaceutical Co., Ltd, to co-develop and co-market ED-71 for osteoporosis in Japan
- May R1678 :Decided to join multinational phase II study conducted by Roche for schizophrenia
- Jun EPOCH(EPOGIN) :Started additional phase III study for treatment of chemotherapy-induced anemia
- Jun R1579 :Started phase I study for type II diabetes
- Jul AVS :Withdrew the application and suspended the development for subarachnoidal hemorrhage because the additional phase III study under review did not meet the endpoint
- Jul SG-75 :Licensed-out the import and marketing rights to Merck Pharmaceutical (HK) Ltd. in China
- Jul MRA(Actemra) :Obtained positive recommendation from FDA AdCom

# Projected Submissions

Filings planned each year



## Contacts:

### Corporate Communications Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607

e-mail: [pr@chugai-pharm.co.jp](mailto:pr@chugai-pharm.co.jp)

Masayuki Yamada, Seiji Shimada, Hiroshi Araki

### Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607

e-mail: [ir@chugai-pharm.co.jp](mailto:ir@chugai-pharm.co.jp)

Mac Uchida, Kae Maeda, Tomoko Shimizu, Yusuke Tokita